DURHAM, N.C., DECEMBER 5, 2017 — The outlook for orphan drug research is more promising than ever, with regulators providing a progressive development platform and government reforms putting new emphasis on the need to treat rare diseases. Premier Research will examine the outlook for biotech and pharma companies at a live webinar on Tuesday, December 5, at 11 a.m. EST / 4 p.m. GMT / 5 p.m. CST.
Improving Regulatory and Operational Performance in Orphan Drug Development will explore pathways, incentives, and engagement opportunities that are helping bring innovative treatments to market faster. Topics will include:
- Regulatory and operational nuances particular to orphan drug development.
- The benefits of early planning and regulatory engagement.
- Operationalizing trials to support orphan designation.
We’ll also discuss the importance of involving patient groups, strategies for identifying patients, how to pick investigative sites, and much more. Register now — it will be an informative hour.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech, specialty pharma, and medical device companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.